Asthenic and cognitive disorders after the COVID-19 infection
DOI: 10.32364/2587-6821-2021-5-10-636-641
P.R. Kamchatnov1, E.Yu. Solov’eva1, D.R. Khasanova2, V.V. Fateeva3
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Kazan State Medical University, Kazan, Russian Federation
3I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Asthenic disorders are one of the most critical and challenging issues in various medical disciplines. Postinfectious asthenia is relatively common. Its major presentations are a significant long-lasting physical and intellectual fatigue. The COVID-19 infection results in numerous emotional, cognitive, and vegetative disorders, drastically reducing the quality of life and preventing rehabilitation and returning to baseline everyday activity. The rationale for introducing the term "post-COVID syndrome" is accounted for by the high prevalence of asthenic, cognitive, and vegetative disorders after the COVID-19 infection and their higher rate compared to other infections and a significant reduction in the quality of life. This paper discusses clinical presentations of the post-COVID syndrome and analyzes the findings on the pathogenesis of this condition. The authors declare that all patients after the COVID-19 infection should undergo the assessment of cognitive functions and asthenic syndrome followed by adequate treatment prescription. The paper describes treatment modalities for the post-COVID syndrome, e.g., the perspective use of Prospecta®, which demonstrated the efficacy for acute and chronic disorders of brain circulation.
Keywords: COVID-19, post-COVID syndrome, asthenic disorders, cognitive disorders, Prospecta.
For citation: Kamchatnov P.R., Solov’eva E.Yu., Khasanova D.R., Fateeva V.V. Asthenic and cognitive disorders after the COVID-19 infection. Russian Medical Inquiry. 2021;5(10):636–641 (in Russ.). DOI: 10.32364/2587-6821-2021-5-10-636-641
About the authors:
Pavel R. Kamchatnov — Dr. Sc. (Med.), professor of the Department of Neurology and Neurosurgery of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0001-6747-3476.
Ella Yu. Solov’eva — Dr. Sc. (Med.), Head of the Department of Neurology and Neurosurgery of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0003-1256-2695.
Dina R. Khasanova — Dr. Sc. (Med.), professor of the Department of Neurology and Neurosurgery of the Faculty of Advanced Training and Professional Education, Kazan State Medical University; 49, Butlerov str., Kazan, 420012, Russian Federation; ORCID iD 0000-0002-8825-2346.
Viktoriya V. Fateeva — C. Sc. (Med.), professor of the Department of Nervous Diseases of the Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University); 8 Build. 2, Trubetskaya str., Moscow, 119991, Russian Federation; ORCID iD 0000-0001-9935-3962.
Contact information: Pavel R. Kamchatnov, e-mail: pavkam7@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 23.08.2021.
Revised 15.09.2021.
Accepted 30.09.2021.
2. Hickie I., Davenport T., Wakefield D. et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. DOI: 10.1136/bmj.38933.585764.AE.
3. Katz B.Z., Shiraishi Y., Mears C.J. et al. Chronic fatigue syndrome following infectious mononucleosis in adolescents. Pediatrics. 2009;124:189–193. DOI: 10.1542/peds.2008-1879.
4. Naess H., Nyland M., Hausken T. et al. Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence. BMC Gastroenterol. 2012;12(1):13. DOI: 10.1186/1471-230X-12-13.
5. Preedy V.R., Smith D.G., Salisbury J.R. et al. Biochemical and muscle studies in patients with acute onset post-viral fatigue syndrome. J Clin Pathol. 1993;46(8):722–726. DOI: 10.1136/jcp.46.8.722.
6. Carruthers B.M., Jain A.K., De Meirleir K.L. et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome. 2003;11(1):7–115. DOI: 10.1300/J092v11n01_02.
7. Fukuda K., Straus S.E., Hickie I. et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. international chronic fatigue syndrome study group. Ann Intern Med. 1994;121(12):953–959. DOI: 10.7326/0003-4819-121-12-199412150-00009.
8. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. (Electronic resourсe.) URL: https://www.nice.org.uk/guidance/ng188. (access date: 10.08.2021)
9. Fauci Introduces New Acronym for Long COVID at White House Briefing. Medscape (Electronic resourсe.) URL: https://www.medscape.com/viewarticle/946419. (access date:10.08.2021).
10. Rudroff T., Fietsam A.C., Deters J.R. et al. Post-COVID-19 Fatigue: Potential Contributing Factors. Brain Sci. 2020;10(12):1012. DOI: 10.3390/brainsci10121012.
11. Frontera J.A., Lewis A., Melmed K. et al. Prevalence and Predictors of Prolonged Cognitive and Psychological Symptoms Following COVID-19 in the United States. Front Aging Neurosci. 2021;13:690383. DOI: 10.3389/fnagi.2021.690383.
12. Larsen N.W., Stiles L.E., Miglis M.G. Preparing for the long-haul: Autonomic complications of COVID-19. Auton Neurosci. 2021;235:102841. DOI: 10.1016/j.autneu.2021.102841.
13. Townsend L., Dyer A., Jones K. et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. DOI: 10.1371/journal.pone.0240784.
14. Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. DOI: 10.1038/s41598-021-95565-8.
15. Stavem K., Ghanima W., Olsen M.K. et al. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study. Int J Environ Res Public Health. 2021;18(4):2030. DOI: 10.3390/ijerph18042030.
16. Willi S., Lüthold R., Hunt A. et al. COVID-19 sequelae in adults aged less than 50 years: A systematic review. Travel Med Infect Dis. 2021;40:101995. DOI: 10.1016/j.tmaid.2021.101995.
17. Moldofsky H., Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37. DOI: 10.1186/1471-2377-11-37.
18. Tansey C.M., Louie M., Loeb M. et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch. Int. Med. 2007;167(12):1312–1320. DOI: 10.1001/archinte.167.12.1312.
19. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603–605. DOI: 10.1001/jama.2020.12603.
20. Fukuda K., Straus S.E., Hickie I. et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(11):953–959. DOI: 10.7326/0003-4819-121-12-199412150-00009.
21. Cockshell S.J., Mathias J.L. Cognitive deficits in chronic fatigue syndrome and their relationship to psychological status, symptomatology, and everyday functioning. Neuropsychology. 2013;27(2):230–242. DOI: 10.1037/a0032084.
22. Schmaling K., Betterton K. Neurocognitive complaints and functional status among patients with chronic fatigue syndrome and fibromyalgia. Qual Life Res. 2016;25(5):1257–1263. DOI: 10.1007/s11136-015-1160-y.
23. Ickmans K., Meeus M., Kos D. et al. Cognitive performance is of clinical importance, but is unrelated to pain severity in women with chronic fatigue syndrome. Clin Rheumatol. 2013;32(10):1475–1485. DOI: 10.1007/s10067-013-2308-1.
24. Kanberg N., Simrén J., Edén A. et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine. 2021;70:103512. DOI: 10.1016/j.ebiom.2021.103512.
25. Edén A., Simrén J., Price R.W. et al. Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis. J Neurochem. 2021;159(1):61–77. DOI: 10.1111/jnc.15459.
26. Meppie E., Peiffer-Smadja N., Maury A. et al. Neurological manifestations associated with COVID-19: A multicentric registry. Clin Microbiol Infect. 2021;27(3):458–466. DOI: 10.1016/j.cmi.2020.11.005.
27. Virhammar J., Nääs A., Fällmar D. et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2021;28(10):3324–3331. DOI: 10.1111/ene.14703.
28. Baig A.M., Khaleeq A., Ali U., Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020;11(7):995–998. DOI: 10.1021/acschemneuro.0c00122.
29. Garg M., Maralakunte M., Garg S. et al. The Conundrum of ‘Long-COVID-19’: A Narrative Review. Int J Gen Med. 2021;14:2491–2506. DOI: 10.2147/IJGM.S316708.
30. Rudroff T., Fietsam A.C., Deters J.R. et al. Post-COVID-19 Fatigue: Potential Contributing Factors. Brain Sci. 2020;10(12):1012. DOI: 10.3390/brainsci10121012.
31. Chen G., Wu D., Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. DOI: 10.1172/JCI137244.
32. Abenza-Abildúa M.J., Novo-Aparicio S., Moreno-Zabaleta R. et al. Encephalopathy in severe SARS-CoV2 infection: Inflammatory or infectious? Int J Infect Dis. 2020;98:398–400.
33. Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M. et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. DOI: 10.1016/j.cytogfr.2020.06.001.
34. Asby D., Boche D., Allan S. et al. Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease. Brain. 2021;144(6):1869–1883. DOI: 10.1093/brain/awab094.
35. Humphreys H., Kilby L., Kudiersky N., Copeland R. Long COVID and the role of physical activity: a qualitative study. BMJ Open. 2021;11(3):e047632. DOI: 10.1136/bmjopen-2020-047632.
36. Ferraro F., Calafiore D., Dambruoso F. et al. COVID-19 related fatigue: Which role for rehabilitation in post-COVID-19 patients? A case series. J Med Virol. 2021;93(4):1896–1899. DOI: 10.1002/jmv.26717.
37. Smits M., Staal J.B., van Goor H. Could Virtual Reality play a role in the rehabilitation after COVID-19 infection? BMJ Open Sport Exerc Med. 2020;6(1):e000943. DOI: 10.1136/bmjsem-2020-000943.
38. Вознюк И.А., Заваденко Н.Н., Камчатнов П.Р. и др. Итоги круглого стола: современные подходы к медикаментозной терапии когнитивных нарушений при цереброваскулярной патологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(8):147–152. DOI: 10.17116/jnevro2021121081147. [Voznyuk I.A., Zavadenko N.N., Kamchatnov P.R. et al. Results of the round table: modern approaches to drug therapy of cognitive impairment in cerebrovascular pathology. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2021;121(8):147–152 (in Russ.)]. DOI: 10.17116/jnevro2021121081147.
39. Белова А.Н., Богданов Э.И., Вознюк И.А. и др. Терапия умеренных когнитивных расстройств в раннем восстановительном периоде ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(5):33–39. DOI: 10.17116/jnevro202112105133. [Belova A.N., Bogdanov E.I., Voznyuk I.A. et al. Therapy of moderate cognitive disorders in the early recovery period of ischemic stroke. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2021;121(5):33–39 (in Russ.)]. DOI: 10.17116/jnevro202112105133.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
